Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

GP KFPs / SAQsrespiratory-health

GP KFPs / SAQs · respiratory-health

COPD — KFP-style written assessment

KFP-style staged scenarios on COPD in general practice: confirming the diagnosis and grading it correctly, building the cessation plan with pharmacotherapy evidence, deciding who gets ICS using IMPACT/ETHOS/WISDOM logic, managing an exacerbation in the community per Anthonisen and REDUCE, and assessing for long-term oxygen therapy.

30 marks45 min3 min readVerification in progress

Target exams

RACGP KFPRACGP AKTMRCGP AKT
On this page
Study tools

Target exams

RACGP KFPRACGP AKTMRCGP AKT
Prompt
COPD: confirm it spirometrically, stop the smoke, target the inhalers, treat the exacerbation — definition, cessation pharmacotherapy, ICS decisions and exacerbation care

KFP 1 (10 marks)

A 59-year-old painter who has smoked 25 cigarettes daily for 35 years presents with two years of worsening exertional breathlessness and morning sputum. Spirometry: post-bronchodilator FEV1/FVC 0.58; FEV1 58% predicted. He wants 'something to fix my lungs'. [1] [3] [5]

  1. State the diagnostic criterion he meets and grade his airflow limitation. (3) [1]
  2. What can and cannot be achieved by smoking cessation at this stage? Quantify the pharmacotherapy you would offer. (5) [3] [6] [7]
  3. His brother asks whether he should have a 'breathing test' too — he feels well. What is the correct screening position? (2) [2]

Model answers

  1. Post-bronchodilator FEV1/FVC below 0.70 confirms COPD — no reversibility requirement. FEV1 58% predicted = GOLD grade 2 (moderate). [1]
  2. Cessation cannot restore lost lung function — irreversible obstructive changes are established — but it reverts the rate of further FEV1 loss toward normal, and in established COPD improves FEV1% predicted (+6.72%), symptoms, walk distance and may reduce mortality. Offer varenicline first-line (RR 2.24 versus placebo; superior to patch RR 1.25 and bupropion), or combination NRT which performs comparably; bupropion equals single-form NRT. Neuropsychiatric safety of varenicline is confirmed (EAGLES). [3] [6] [7] [9]
  3. The USPSTF recommends against screening asymptomatic adults for COPD — no net benefit. Case-finding applies only to those with respiratory symptoms plus risk factors. [2]
General Practice Pro

Continue reading

You have read the opening of this kfps / saq. The complete unit — every section and its primary-source references — is part of the General Practice fellowship library.

Sign in to continueSee pricing
References15ShowHide
  1. [1]Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023.PMID 36858443
  2. [2]Mangione CM, Barry MJ, Nicholson WK, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA, 2022.PMID 35536260
  3. [3]Fletcher C, Peto R The natural history of chronic airflow obstruction. Br Med J, 1977.PMID 871704
  4. [5]Wang Z, Qiu Y, Ji X, Dong L Effects of smoking cessation on individuals with COPD: a systematic review and meta-analysis. Front Public Health, 2024.PMID 39722704
  5. [6]Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016.PMID 27158893
  6. [7]Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016.PMID 27116918
  7. [9]Cahill K, Stevens S, Perera R, Lancaster T Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 2013.PMID 23728690
  8. [12]Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med, 2016.PMID 27181606
  9. [13]Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med, 2014.PMID 25196117
  10. [14]Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016.PMID 27066739
  11. [15]Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res, 2020.PMID 32943047
  12. [16]Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987.PMID 3492164
  13. [17]Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 2013.PMID 23695200
  14. [18]Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2017.PMID 28702957
  15. [23]Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, et al. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2022.PMID 35001366
General Practice Pro

$29/ monthor $279 / year

The complete General Practice library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCommunity-acquired pneumonia — KFP-style written assessmentrespiratory-healthNextLung cancer suspicion — KFP-style written assessmentrespiratory-health